Kanungo Shibani, Morton Jacob, Neelakantan Mekala, Ching Kevin, Saeedian Jasmine, Goldstein Amy
Department of Pediatric and Adolescent Medicine, Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, Michigan, USA.
Children's Hospital of Philadelphia and Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Ann Transl Med. 2018 Dec;6(24):475. doi: 10.21037/atm.2018.12.13.
Primary mitochondrial disorders are a group of clinically variable and heterogeneous inborn errors of metabolism (IEMs), resulting from defects in cellular energy, and can affect every organ system of the body. Clinical presentations vary and may include symptoms of fatigue, skeletal muscle weakness, exercise intolerance, short stature, failure to thrive, blindness, ptosis and ophthalmoplegia, nystagmus, hearing loss, hypoglycemia, diabetes mellitus, learning difficulties, intellectual disability, seizures, stroke-like episodes, spasticity, dystonia, hypotonia, pain, neuropsychiatric symptoms, gastrointestinal reflux, dysmotility, gastrointestinal pseudo-obstruction, cardiomyopathy, cardiac conduction defects, and other endocrine, renal, cardiac, and liver problems. Most phenotypic manifestations are multi-systemic, with presentations varying at different age of onset and may show great variability within members of the same family; making these truly complex IEMs. Most primary mitochondrial diseases are autosomal recessive (AR); but maternally-inherited [from mitochondrial (mt) DNA], autosomal dominant and X-linked inheritance are also known. Mitochondria are unique energy-generating cellular organelles, geared for survival and contain their own unique genetic coding material, a circular piece of mtDNA about 16,000 base pairs in size. Additional nuclear (n)DNA encoded genes maintain mitochondrial biogenesis by supervising mtDNA replication, repair and synthesis, which is modified during increased energy demands or physiological stress. Despite our growing knowledge of the hundreds of genetic etiologies for this group of disorders, diagnosis can also remain elusive due to unique aspects of mitochondrial genetics. Though cure and FDA-approved therapies currently elude these IEMs, and current suggested therapies which include nutritional supplements and vitamins are of questionable efficacy; multi-center, international clinical trials are in progress for primary mitochondrial disorders.
原发性线粒体疾病是一组临床症状多样且异质性的先天性代谢缺陷病(IEMs),由细胞能量缺陷引起,可影响身体的各个器官系统。临床表现各不相同,可能包括疲劳、骨骼肌无力、运动不耐受、身材矮小、生长发育迟缓、失明、上睑下垂和眼肌麻痹、眼球震颤、听力丧失、低血糖、糖尿病、学习困难、智力残疾、癫痫发作、类中风发作、痉挛、肌张力障碍、肌张力减退、疼痛、神经精神症状、胃食管反流、动力障碍、胃肠道假性梗阻、心肌病、心脏传导缺陷以及其他内分泌、肾脏、心脏和肝脏问题。大多数表型表现是多系统的,在不同发病年龄表现各异,且在同一家族成员中可能有很大差异;这使得这些疾病成为真正复杂的IEMs。大多数原发性线粒体疾病是常染色体隐性遗传(AR);但也存在母系遗传(来自线粒体(mt)DNA)、常染色体显性遗传和X连锁遗传。线粒体是独特的产生能量的细胞器,为生存而设计,并且含有自己独特的遗传编码物质,一个大小约为16000个碱基对的环状mtDNA。另外,由核(n)DNA编码的基因通过监督mtDNA复制、修复和合成来维持线粒体生物合成,在能量需求增加或生理应激期间,这种合成会发生改变。尽管我们对这组疾病的数百种遗传病因的了解越来越多,但由于线粒体遗传学的独特方面,诊断仍可能难以捉摸。尽管目前这些IEMs尚无治愈方法和FDA批准的疗法,且目前建议的包括营养补充剂和维生素的疗法疗效存疑;但针对原发性线粒体疾病的多中心国际临床试验正在进行中。